NICE Single Technology Appraisal Guidance No 260 –
Botulinum toxin type A for the prevention of headaches in adults
with chronic migraine
This NICE guidance was published on 27 June 2012. The web
reference for the appraisal and other related documents is:
www.nice.org.uk/TA260
NHSScotland should note that:
1. Recommendations of NICE Single Technology
Appraisals (STAs) have no status in NHSScotland.
2. NHS boards should adhere to the Scottish
Medicines Consortium (SMC) advice.
SMC published a Statement of Advice (692/11) on
this medication for this indication in April 2011. This stated
that:
botulinum toxin type A (Botox®) is not
recommended for use within NHSScotland for the prophylaxis of
headaches in adults with chronic migraine (headaches on at least 15
days per month of which at least 8 days are with migraine).
Access the advice of SMC
3. There is a material difference between the
recommendations of the NICE STA and SMC. NICE recommended the
medicine as a treatment option in patients whose condition has not
responded to at least three prior pharmacological prophylaxis
therapies and is appropriately managed for medication overuse.
If you need further assistance, please contact
Eleanor Brownlee in the first instance (tel 0141 225 6873 or email
eleanor.brownlee@nhs.net).
Published Date: 27 June 2012
